NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10,912 mln
Float67.11 mln
Earnings Date09/21/2026
1-Year Forecast
166
Strong upside
Relative Strength
63
/ 100
Outperforming
Debt / Equity
0.00
Debt-free
ROE
-124
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
ABIVAX is a Paris-based drug development company founded in 2013, focused on creating treatments that work with the body's own immune system to manage long-term inflammatory conditions. Its most advanced medicine, obefazimod, is currently being tested in late-stage trials for ulcerative colitis and earlier-stage trials for Crohn's disease.
